[Diagnosing Fauci’s Book](https://wbbsec.com/opinions-and-features/diagnosing-faucis-book-on-call-a-doctors-journey-in-public-service/)
[Diagnosing Fauci’s Book](https://wbbsec.com/opinions-and-features/diagnosing-faucis-book-on-call-a-doctors-journey-in-public-service/)
In: Press Releases

Executive Teams of Emerging Biotech Companies Present to Investor Community

For Immediate Release

September 8, 2017

SAN DIEGO, CA – WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference.  The Newsmakers conference is hosted annually by BioCentury and will take place at the Millennium Broadway Hotel and Conference Center in New York City on Friday, September 8, 2017.

BioCentury’s NewsMakers conference allows emerging biotechnology companies to help identify investment and partnering prospects.  The objective of the NewsMakers conference is to provide pharmaceutical executives, investment funds, and venture capitalists a venue to connect with investor-validated, milestone-rich private and public companies in key therapeutic areas for potential investment and partnership opportunities.  NewsMakers in the Biotech Industry is recognized as the industry’s key venue for companies to take their story to Wall Street each fall.

About WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities.

WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients. The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. www.wbbsec.com

About BioCentury

Since 1993, BioCentury Publications, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.  BioCentury’s Editorial and Research staff comprises industry-recognized business and science editors and writers. The Company’s management team includes executives with backgrounds in international business, publishing, finance, and the biotech and pharmaceutical industries. www.biocentury.com